The future of #drugdiscovery is here, and it's powered by AI. At Healx, we utilize #AI to develop new treatments for #rarediseases. Not only can the use of AI help reduce costs and timelines, it can open the doors for greater scalability, thus reaching a broader patient population. Read more about the power of AI in #biotech in this article from The Times.
Healx
Biotechnology Research
Cambridge, Cambridgeshire 17,560 followers
AI-powered and patient-inspired. We accelerate the discovery and development of rare disease treatments.
Über uns
Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
- Website
-
http://www.healx.ai
External link for Healx
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Cambridge, Cambridgeshire
- Typ
- In Privatbesitz
- Gegründet
- 2014
Standorte
-
Primäre
Wegbeschreibung erhalten
66-68 Hills Rd
Charter House
Cambridge, Cambridgeshire CB21LA, GB
Employees at Healx
Aktualisierungen
-
Healx reposted this
I just read a truly inspiring post from my dear friend, Dr Jack Kreindler, describing the parallels between Michelangelo’s ‘David’ and the battles we face in Biotech. In the fight against rare diseases, it's even more the case. We often feel like David going up against Goliath. The challenges are immense, and the odds can seem overwhelming. But as Michelangelo’s ‘David’ teaches us, true innovation often comes from the most unexpected places. At Healx, we’re on a relentless quest to discover new medicines for those who need them most—patients with rare diseases who have long been overlooked. 95% of rare diseases don't have an approved treatment today. Our weapon of choice in this battle? AI-driven drug discovery. Just as David used his slingshot with precision, we use advanced AI to pinpoint and develop treatments with unparalleled accuracy, targeting the very roots of complex diseases. Rare diseases represent one of the greatest unmet needs in medicine, with over 300 million patients around the world still waiting for effective treatments. But with every breakthrough, every step forward, we’re proving that even the smallest, most focused efforts can make a world of difference. Together, we’re carving out a new path in healthcare—one that stands tall against the giants of the industry, not by sheer size or force, but by innovation, passion, and a commitment to those who have been forgotten for too long. #RareDiseases #AI #Biotech #Innovation #DavidVsGoliath #DrJack
Physician & Explorer. Founder, CEO @WellFounded. Researching the limits of human performance & healthy longevity.
What can Michelangelo’s ‘David’ teach us about the battles hard-fought by #Biotech to beat the Goliaths of #Pharma? Little did I know that, at the time, Michelangelo was just a 26 when he fought to win the commission to sculpt this herculean monolith of David - as one of 12 biblical prophets to adorn and support the base of Brunelleschi’s legendary and still the world’s largest brick Dome of Florence Cathedral, itself a 129 year Phase 1 symbol of defiance by the free Florentine Republic against the Medici’s all powerful and encircling presence. It was 523 years ago. 1501. He took a deep breath and raised his hand. Michelangelo was up against the greatest, most influential sculptors of the era. Donatello, Duccio, Agostino, Bandinelli, Sansovino and even the great Leonardo da Vinci were consulted. The Vatican and Republic’s Counsel of 12 favoured his bold vision. The luck he created for himself followed by 2 years of painstaking application of genius was ground breaking. So striking and exceptional was this work that once finished in 1504 it had to be protected from destruction from those who saw for what it actually was, an icon of poised confidence with simple but lethal weaponary against the giants of the era. The weaponary being the power of democracy and freedom to innovate. David is to the world of artistic expression and political symbolism what antibiotics are to medicine. We’re habituated to both now. We walk past David just like we pop 500mg of Penicillin often without realising how much the world changed since. The metaphor for medicine is profound. Like a bold new venture backed ecosystem the Republic fought for, often to the death, to earn its independence disrupting the conservative rule of those preserving their industrial and political control. Yet even among this new innovation economy there was fierce competition between startups and founders established and new comers. It was not just tenacity and talent that led Michelango to succeed in his mission for David and longterm vision thereafter, that detonated a Renaissance for mankind from which we still reap huge benefits. He carved David from a blocky first cut by his elders and was not solely self taught. He was a giant that created a giant by standing on the shoulders of giants funded by the boldest thinkers and investors of his era. This is much the same as in Biotechnology. If you are in the Biotech space, investing or building, and wondering how on Earth you can carve a meaningful change to the fossilised incentives and disease-dependent rule of the big blockbuster industry, in your lifetime, you can’t go wrong with the story of Michelango’s David in your mindset. The extraordinary poise, fluidity of posture, even if not moved in 5 centuries, those hands holding the simplest of weapons, and those eyes knowing exactly where and when to strike. This is how the Innovator prevails. This is how the Underdog wins. This is how #David beats #Goliath. 📸 by my iPhone
-
-
Neurofibromatosis type 1 (#NF1) is a rare genetic disorder associated with predisposition to develop multiple benign and malignant tumors along the nerves. By combining generative #AI technology with deep drug discovery and development expertise, we are aiming to accelerate the pace, increase the scale and improve the chance of success of treatment development for patients. Our Head of Neurofibromatosis Therapy Development Simone Manso talks more about our approach and the hope we have for more treatment options below.
-
We're incredibly excited for the opportunities that lie ahead following today's news. Learn more about our mission and our AI approach for finding treatments for #rarediseases, including #NF1, in this feature with BiotechTV below.
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today. Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for neurofibromatosis Type 1 into a phase 2 study. Full video: https://lnkd.in/gZFRqcFf BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
It's truly a pivotal time for our team. We're proud to announce two significant updates: • We raised $47 million in a Series C financing round. • The U.S. FDA has cleared our IND application to advance HLX-1502 in Phase 2 clinical trial in Neurofibromatosis Type 1 (NF1). The Series C financing was co-led by R42 Group and Atomico Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners. Proceeds of the financing will be used to advance our rare oncology, renal and neurodevelopmental disorders pipeline which includes our lead program targeting #NF1, a rare genetic condition that causes tumours to grow along the nerves. With this IND clearance, we plan to initiate the Phase 2 clinical trial for HLX-1502 by the end of 2024. Read more about today's announcements here: https://lnkd.in/eJmXb5Wy
-
-
Discovering safe and effective treatments for rare diseases presents a number of challenges, beginning with the sourcing and integration of diverse data sets that inform #drugdiscovery. We are excited to share our research on an experimentally validated approach to generating automated biological evidence using knowledge graphs has been published in Nature Communications. We extend our sincere gratitude to the Healx team members who are driving this novel approach forward. Check it out here. https://lnkd.in/eq-_YiyY
An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs - Nature Communications
nature.com
-
🚀 New Breakthrough in Computational Drug Discovery! 🚀 Exciting news published in Frontiers in Pharmacology! A cutting-edge study has identified HLX-0607 as a candidate for treating autosomal dominant polycystic kidney disease (ADPKD) through innovative computational drug discovery approaches. ADPKD is a rare kidney disease associated with the progressive growth of kidney cysts and eventually renal failure. To address the significant unmet need for new therapeutic approaches, Healx applied multiple computational drug discovery workflows which identified HLX-0607 as a candidate treatment. Further computational and experimental approaches were applied to understand the mechanism of drug action. Dive into the details of this groundbreaking study and its potential impact on ADPKD treatment. Read the full article here: https://lnkd.in/eKTtFrse #Pharmacology #DrugDiscovery #ADPKD #HealthcareInnovation #ComputationalBiology #ScientificResearch #FrontiersInPharmacology #OpenAccess
Frontiers | Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease
frontiersin.org
-
🌟 Join Us in Making NF Research Visible! 🌟 We're thrilled to share this inspiring video created by our dedicated Healx team as part of the "Make NF Research Visible!" campaign by the Children's Tumor Foundation. This initiative sheds light on the importance of Neurofibromatosis (NF) research and the profound impact it can have on countless lives. In this video, our team members Simone Manso Emma Davies Ian Roberts and Hanna Orr MFPM answer a crucial question: "Why is it important to make NF research visible?" Their insights and passion highlight the urgent need for awareness, funding, and breakthroughs in NF research. 🎥 Watch the video to hear their powerful messages and learn how you can support this vital cause. Together, we can drive progress and hope for those affected by NF. https://lnkd.in/gmbpkmpt #MakeNFResearchVisible #Neurofibromatosis #Healx #Research #Awareness #Hope
Make NF Research Visible: Healx
https://www.youtube.com/
-
We are proud to share how Healx employees and their families united to support NF Awareness Day on May 17th. As part of our commitment to raise awareness for neurofibromatosis (NF), we joined forces with the Children's Tumor Foundation (CTF) for their 'Shine a Light' campaign. In a beautiful display, buildings in Cambridge, UK, and Valencia, Spain, were illuminated in blue and green, the official colors representing NF. Healx is dedicated to support those affected by this condition and our ongoing partnership with CTF. By the lighting of these landmarks, we hope the awareness continues to spread, fostering community support, and advance the fight against NF. Together, we can make a difference. 💙💚 This article in the Cambridge Independant showcases this commitment: https://lnkd.in/eVastwPH #Healx #ShineaLight #NFAwareness #CTF #Neurofibromatosis #CommunitySupport #GlobalInitiative #BiotechCares
Healx: Shining a light on nerve disease - and treatments
cambridgeindependent.co.uk
-
🌟 Shining a Light on NF Awareness Day 🌟 We are thrilled to announce that, as well as the team turning up and turning blue and green in the office, members of the Healx team and their families helped support the global "Shine a Light" campaign on 17th May, lighting up buildings in blue and green for NF awareness day. A heartfelt thank you to Miguel Pignatelli, Daniel Mason and Megan Pullein, and everyone else who made this possible, as well as the City of Arts and Sciences and Veles e vents building in Valencia, Spain, the Cambridge Corn Exchange and Ely Cathedral in the UK who took part!🎗️ Neurofibromatosis (NF) is a genetic disorder that affects millions worldwide, and this initiative helps to raise visibility and support for the NF community. By illuminating landmarks around the globe we all help spread awareness and advocate for better understanding and treatment of NF. Let's continue to support and shine a light on NF together! #NFAwarenessDay #ShineALight #EndNF #ChildrensTumor #NervetumoursUK Children's Tumor Foundation
-
-
-
-
-
+2
-